Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA.
Company profile
Ticker
AGEN
Exchange
Website
CEO
Garo Armen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
ANTIGENICS INC /DE/
SEC CIK
Corporate docs
IRS number
61562417
AGEN stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
23 Dec 22
S-3ASR
Automatic shelf registration
23 Dec 22
8-K
Entry into a Material Definitive Agreement
2 Dec 22
8-K
Agenus Provides Corporate Update and Third Quarter 2022 Financial Report
8 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
S-8
Registration of securities for employees
11 Aug 22
8-K
Agenus Provides Corporate Update and Second Quarter 2022 Financial Report
9 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Amendments to Articles of Incorporation or Bylaws
5 Aug 22
DEF 14A
Definitive proxy
22 Jun 22
Transcripts
AGEN
Earnings call transcript
2022 Q3
8 Nov 22
AGEN
Earnings call transcript
2022 Q2
9 Aug 22
AGEN
Earnings call transcript
2022 Q1
10 May 22
AGEN
Earnings call transcript
2021 Q4
1 Mar 22
AGEN
Earnings call transcript
2021 Q3
9 Nov 21
AGEN
Earnings call transcript
2021 Q2
9 Aug 21
AGEN
Earnings call transcript
2021 Q1
6 May 21
AGEN
Earnings call transcript
2020 Q4
15 Mar 21
AGEN
Earnings call transcript
2020 Q3
29 Oct 20
AGEN
Earnings call transcript
2020 Q2
6 Aug 20
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 211.02 mm | 211.02 mm | 211.02 mm | 211.02 mm | 211.02 mm | 211.02 mm |
| Cash burn (monthly) | 6.68 mm | 4.01 mm | 13.88 mm | 14.64 mm | 10.73 mm | 12.58 mm |
| Cash used (since last report) | 26.42 mm | 15.89 mm | 54.93 mm | 57.94 mm | 42.46 mm | 49.78 mm |
| Cash remaining | 184.60 mm | 195.14 mm | 156.09 mm | 153.09 mm | 168.56 mm | 161.24 mm |
| Runway (months of cash) | 27.6 | 48.6 | 11.2 | 10.5 | 15.7 | 12.8 |
Institutional ownership, Q3 2022
57.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 167 |
| Opened positions | 24 |
| Closed positions | 13 |
| Increased positions | 65 |
| Reduced positions | 42 |
| 13F shares | Current |
|---|---|
| Total value | 396.29 mm |
| Total shares | 175.28 mm |
| Total puts | 310.10 k |
| Total calls | 1.56 mm |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Deep Track Capital | 26.33 mm | $53.97 mm |
| Vanguard | 22.85 mm | $46.85 mm |
| BLK Blackrock | 21.56 mm | $44.20 mm |
| INCY Incyte | 12.07 mm | $38.87 mm |
| GILD Gilead Sciences | 11.11 mm | $35.78 mm |
| Larry N Feinberg | 8.42 mm | $27.10 mm |
| Point72 Asset Management | 8.37 mm | $17.16 mm |
| Renaissance Technologies | 5.13 mm | $10.52 mm |
| Geode Capital Management | 4.82 mm | $9.88 mm |
| Oracle Investment Management | 4.49 mm | $9.21 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 8 Jan 23 | Wiinberg Ulf | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 100,000 | 240.00 k | 100,000 |
| 8 Jan 23 | Susan B Hirsch | Stock Option Common Stock | Grant | Acquire A | No | No | 2.4 | 100,000 | 240.00 k | 100,000 |
| 5 Jan 23 | Steven J O'Day | Common Stock | Grant | Acquire A | No | No | 2.45 | 109,381 | 267.98 k | 272,384 |
| 5 Jan 23 | Steven J O'Day | Stock Option Common Stock | Grant | Acquire A | No | No | 2.45 | 200,000 | 490.00 k | 200,000 |
| 5 Jan 23 | Klaskin Christine M | Common Stock | Grant | Acquire A | No | No | 2.45 | 31,294 | 76.67 k | 153,937 |
| 5 Jan 23 | Klaskin Christine M | Stock Option Common Stock | Grant | Acquire A | No | No | 2.45 | 162,916 | 399.14 k | 162,916 |
| 5 Jan 23 | Armen Garo H | Common Stock | Grant | Acquire A | No | No | 2.45 | 241,383 | 591.39 k | 1,249,167 |
| 5 Jan 23 | Armen Garo H | Stock Option Common Stock | Grant | Acquire A | No | No | 2.45 | 2,400,000 | 5.88 mm | 2,400,000 |
News
Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate
23 Jan 23
Agenus Presents Clinical Data Demonstrating Durable Responses Of Botensilimab/Balstilimab Combination In Metastatic Microsatellite Stable Colorectal Cancer At ASCO GI
23 Jan 23
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
22 Dec 22
EF Hutton Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $8.3
22 Dec 22
EF Hutton Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $8.3
8 Dec 22
Press releases
Agenus to Participate in February Investor Conferences
26 Jan 23
Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
23 Jan 23
Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI
21 Dec 22
Agenus to Participate at 5th Annual Evercore ISI HealthCONx Conference
16 Nov 22
Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers
14 Nov 22